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Mucin 1/Krebs von den Lungen‑6 (KL‑6) is proposed as a serum biomarker of several interstitial lung 
diseases (ILDs), including connective tissue disorders associated with ILD. However, it has not been 
studied in a large cohort of Caucasian antisynthetase syndrome (ASSD) patients. Consequently, 
we assessed the role of MUC1 rs4072037 and serum KL‑6 levels as a potential biomarker of ASSD 
susceptibility and for the differential diagnosis between patients with ILD associated with ASSD 
(ASSD‑ILD +) and idiopathic pulmonary fibrosis (IPF). 168 ASSD patients (149 ASSD‑ILD +), 174 IPF 
patients and 523 healthy controls were genotyped for MUC1 rs4072037 T > C. Serum KL‑6 levels were 
determined in a subgroup of individuals. A significant increase of MUC1 rs4072037 CC genotype 
and C allele frequencies was observed in ASSD patients compared to healthy controls. Likewise, 
MUC1 rs4072037 TC and CC genotypes and C allele frequencies were significantly different between 
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ASSD‑ILD+ and IPF patients. Additionally, serum KL‑6 levels were significantly higher in ASSD 
patients compared to healthy controls. Nevertheless, no differences in serum KL‑6 levels were found 
between ASSD‑ILD+ and IPF patients. Our results suggest that the presence of MUC1 rs4072037 
C allele increases the risk of ASSD and it could be a useful genetic biomarker for the differential 
diagnosis between ASSD‑ILD+ and IPF patients.
Antisynthetase syndrome (ASSD) is a connective tissue disease (CTD) within the group of idiopathic inflamma-
tory myopathies (IIMs), mainly characterized by the clinical triad of arthritis, myositis and interstitial lung dis-
ease (ILD). In this regard, ILD is the most common and serious internal organ involvement of ASSD  patients1–5. 
However, the pathogenesis of ASSD is still unclear and its diagnosis is somewhat delayed when typical features 
are absent. Consequently, further research in this context is needed.
Mucin 1, better known as Krebs von den Lungen-6 (KL-6), is one of the key transmembrane mucins in the 
lung, mainly implicated in processes of cellular proliferation, growth and apoptosis, with increased expression in 
injured or regenerating epithelial  cells6–8. Its role as a serum biomarker has been widely studied in several ILDs, 
including idiopathic pulmonary fibrosis (IPF) and CTDs associated with ILD (CTD-ILD). In fact, it is consid-
ered as a useful marker of epithelial lung damage and a predictor of fibrotic progression in these  diseases6–17. In 
addition, the functional polymorphism rs4072037, located at nucleotide position 568 in the exon 2 of MUC1 
gene, affects serum KL-6  levels9,14,18–21. An association between MUC1 rs4072037 and diverse pathologies has 
also been  reported21–24.
There are several studies focused on the association of KL-6 with other IIMs, mainly polymyositis (PM) and 
dermatomyositis (DM), that indicate a relevant role of this marker in the development and progression of ILD 
in this  context12,16,17,25–30. However, to the best of our knowledge, the effect of MUC1 rs4072037 and serum KL-6 
levels in a large cohort of Caucasian patients with ASSD remains to be elucidated. Therefore, in this study we 
evaluated the role of mucin 1/KL-6, at the genetic and serological level, as a potential biomarker of ASSD. For this 
purpose, we aimed to explore its influence on the susceptibility to ASSD and its possible use for the differential 
diagnosis between ASSD patients with ILD (ASSD-ILD +) and patients with IPF.
Methods
Patients and controls. A total of 168 unrelated Spanish patients of European ancestry diagnosed with 
ASSD (149 ASSD-ILD +) were enrolled in this cross-sectional study from the following Spanish hospitals: Hos-
pital Universitario Marqués de Valdecilla (Santander), Hospital Clínico Universitario de Santiago (Santiago de 
Compostela), Hospital Universitario San Cecilio (Granada), Hospital Universitario Araba (Vitoria), Complejo 
Asistencial Universitario de León (León), Hospital Universitario Vall d´Hebron, Hospital Clínico de Barcelona 
and Hospital Universitario de Bellvitge (Barcelona), Hospital Universitario de la Princesa, Hospital Universitario 
La Paz, Hospital Universitario Fundación Jiménez Díaz, and Hospital General Universitario Gregorio Marañón 
(Madrid). As we originally  defined31,32, these patients were recruited if they had an antisynthetase antibody 
positive in at least two determinations along with one or more findings of arthritis, myositis and/or  ILD2–4,33. 
ILD was defined instrumentally by forced vital capacity (FVC) ≤ 80%, forced expiratory volume in one second/
FVC ≥ 70%] and/or diffusing capacity of the lung for carbon monoxide (DLCO) < 80% and interstitial changes 
on chest high-resolution computed  tomography2–4. Antisynthetase autoantibodies were detected by the myositis 
immunoblot kit ‘Euroline Autoimmune Inflammatory Myopathies 16 Ag kit’ (Euroimmun, Luebeck, Germany) 
or ENA (extractable nuclear antigen) screen tests for anti Jo-1 antibodies, in some cases, as we  described32. The 
occurrence of fever, Raynaud’s phenomenon and mechanic’s hands was also  recorded34,35. Patients with other 
IIMs were excluded. Demographic and clinical characteristics of the whole cohort of ASSD patients included in 
this study have been previously  reported32.
In addition, 174 unrelated Spanish patients of European ancestry who fulfilled the American Thoracic Soci-
ety/European Respiratory Society classification and diagnosis criteria for  IPF36,37 were recruited from Hospital 
Universitario Marqués de Valdecilla (Santander), Hospital Universitario Vall d´Hebrón (Barcelona), Hospital 
Universitario y Politécnico de la Fe (Valencia), and Hospital Universitario 12 de Octubre and Hospital Univer-
sitario Puerta de Hierro (Madrid).
The main demographic and baseline lung function information of ASSD-ILD+ and IPF patients included in 
this study is described in Supplementary table 1.
Moreover, a set of 523 ethnically‐matched healthy controls (44.3% men/55.7% women), without history of 
any autoimmune or pulmonary disease, constituted by blood donors from Hospital Universitario Marqués de 
Valdecilla (Santander) and National DNA Bank Repository (Salamanca), was also included in this study. Their 
mean age ± standard deviation (SD) at the time of the study was 52.8 ± 11.1 years.
For experiments involving humans and the use of human blood samples, all the methods were carried out in 
accordance with the approved guidelines and regulations, according to the Declaration of Helsinki. All experi-
mental protocols were approved by the local Ethics Committee of each participant hospital: Hospital Universi-
tario Marqués de Valdecilla (Santander), Hospital Clínico Universitario de Santiago (Santiago de Compostela), 
Hospital Universitario San Cecilio (Granada), Hospital Universitario Araba (Vitoria), Complejo Asistencial 
Universitario de León (León), Hospital Universitario y Politécnico de la Fe (Valencia), Hospital Universitario 
Vall d´Hebrón, Hospital Clínico de Barcelona and Hospital Universitario de Bellvitge (Barcelona), Hospital 
Universitario de la Princesa, Hospital Universitario La Paz, Hospital Universitario Fundación Jiménez Díaz, 
Hospital General Universitario Gregorio Marañón, Hospital Universitario 12 de Octubre and Hospital Universi-
tario Puerta de Hierro (Madrid). All individuals signed an informed written consent to be included in the study.
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MUC1 rs4072037 genotyping. Genomic DNA from all the patients and healthy controls was extracted 
from peripheral blood using the REALPURE “SSS” kit (RBME04, REAL, Durviz S.L., Valencia, Spain). All the 
individuals were genotyped for MUC1 rs4072037 T > C by a TaqMan assay (C__27532642_10) in a QuantStu-
dio™ 7 Flex real-time polymerase chain reaction system (Applied Biosystems, Foster City, CA, USA). Negative 
controls and duplicate samples were included to check the accuracy of the genotyping.
Determination of serum KL‑6 levels. Serum KL-6 levels were measured in a total of 213 individuals 
(74 ASSD patients (66 ASSD-ILD +), 80 IPF patients and 59 healthy controls) by using a chemiluminescent 
enzyme immunoassay (Lumipulse G KL-6, Fujirebio Iberia SLU) and analyzed in the Fujirebio Lumipulse G600 
II instrument.
Statistical analysis. Data were reported as number of individuals (n), percentage (%), and mean ± SD, as 
appropriate.
All genotype data were checked for deviation from Hardy–Weinberg equilibrium (HWE). Both genotype 
and allele frequencies of MUC1 rs4072037 were calculated and compared between ASSD patients and healthy 
controls as well as between ASSD-ILD+ patients and IPF patients by chi-square test. Strength of associations 
was estimated by logistic regression using odds ratios (OR) and 95% confidence intervals (CI). Results were also 
adjusted for age and sex by logistic regression.
Since ILD is the most serious complication of ASSD and anti Jo-1 the most frequent antisynthetase 
 antibody1–3,5, genetic differences between ASSD patients stratified according to presence/absence of ILD or anti 
Jo-1 antibodies positive/negative were assessed. The strength of associations was estimated by logistic regression 
using OR and 95% CI. Results were also adjusted for age and sex by logistic regression.
Differences in serum levels of KL-6 between two study groups were calculated by Student’s t-test and further 
adjusted for age, sex, and smoking history using ANCOVA.
Given the remarkable difference in men/women ratio between ASSD-ILD+ patients and IPF patients, genetic 
and serum data were also analyzed stratifying the population according to sex.
The influence of MUC1 rs4072037 genotypes and alleles on serum KL-6 levels was tested using linear 
regression.
In all cases, p-values ≤ 0.05 were considered as statistically significant. All statistical analyses were performed 
with STATA statistical software 12/SE (Stata Corp., College Station, TX, USA).
Results
Effect of MUC1 rs4072037 in patients with ASSD. We confirmed that the rs4072037 genotype dis-
tribution was in HWE (p > 0.05). The rate of genotyping success was 100%. We also found that in our study the 
genotype and allele frequencies of MUC1 rs4072037 in healthy controls were similar to the data of the 1000 
Genomes Project for Europeans.
We disclosed a statistically significant increase of MUC1 rs4072037 CC genotype and C allele frequencies in 
the whole cohort of patients with ASSD when compared to healthy controls (Table 1). This increase remained 
marginally significant when adjusted for age and sex (Table 1).
Then, we assessed whether genotype or allele differences of MUC1 rs4072037 existed when patients with 
ASSD were stratified by the presence/absence of ILD. However, no significant differences were observed both 
before and after adjustment for age and sex (Table 2). It was also the case when anti Jo-1 positive ASSD patients 
were compared with anti Jo-1 negative ASSD ones (Table 2).
Furthermore, we analyzed the differences in the genotype or allele frequencies of MUC1 rs4072037 between 
the group of patients with ASSD-ILD+ and patients with IPF. In this regard, a statistically significant increase 
of MUC1 rs4072037 TC and CC genotypes and C allele frequencies were found in ASSD-ILD+ patients when 
compared to those with IPF (Table 3). The same results were obtained after adjustment for age and sex (Table 3). 
When stratified by sex, an increase of MUC1 rs4072037 TC and CC genotypes and C allele frequencies was 
disclosed in women with ASSD-ILD+ when compared to those with IPF (Supplementary table 2). In addition, 
higher MUC1 rs4072037 CC genotype and C allele frequencies were observed in men with ASSD related to those 
with IPF (Supplementary table 3).
Table 1.  Genotype and allele frequencies of MUC1 rs4072037 in ASSD patients and healthy controls. ASSD: 
antisynthetase syndrome; CI: confidence interval; OR: odds ratio. *Adjusted for age and sex.
ASSD % (n) Healthy controls % (n) p OR [95% CI] p* OR [95% CI]*
Genotypes
TT 20.2 (34) 27.2 (142) – Ref. – Ref.
TC 50.6 (85) 49.3 (258) 0.16 1.38 [0.88–2.15] 0.16 1.40 [0.88–2.24]
CC 29.2 (49) 23.5 (123) 0.05 1.66 [1.01–2.74] 0.08 1.60 [0.95–2.71]
Alleles
T 45.5 (153) 51.8 (542) – Ref. – Ref.
C 54.5 (183) 48.2 (504) 0.05 1.29 [1.01–1.65] 0.08 1.26 [0.97–1.63]
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Serum KL‑6 levels in patients with ASSD. Next, we compared serum levels of KL-6 between the 
whole cohort of ASSD patients and healthy controls as well as between ASSD-ILD+ patients and IPF patients. 
In this sense, serum KL-6 levels were significantly higher in patients with ASSD compared to healthy con-
trols (1533.38 ± 1159.76 U/mL vs. 322.39 ± 140.09 U/mL, p = 0.0001, Fig. 1a). However, there was no statistically 
significant difference in serum KL-6 levels between ASSD-ILD+ patients and IPF patients (1653.56 ± 1165.19 
U/mL vs. 1682.23 ± 949.93 U/mL, p = 0.14, Fig.  1b). This was also the case when these patients were strati-
Table 2.  Genotype and allele frequencies of MUC1 rs4072037 in patients with ASSD stratified according to 
the presence/absence of ILD or anti Jo-1 antibodies. ASSD: antisynthetase syndrome; CI: confidence interval; 









% (n) p OR [95% CI] p* OR [95% CI]*
Genotypes
TT 19.5 (29) 20.0 (3) – Ref. – Ref. 18.7 (20) 17.3 (9) – Ref. – Ref.
TC 53.0 (79) 33.3 (5) 0.52 1.63 [0.37–7.28] 0.52 1.64 [0.36–7.52] 54.2 (58) 44.2 (23) 0.79 1.13 [0.45–2.86] 0.82 1.12 [0.43–2.89]
CC 27.5 (41) 46.7 (7) 0.49 0.61 [0.14–2.54] 0.36 0.50 [0.11–2.22] 27.1 (29) 38.5 (20) 0.39 0.65 [0.25–1.72] 0.57 0.75 [0.27–2.03]
Alleles
T 46.0 (137) 36.7 (11) – Ref. – Ref. 45.8 (98) 39.4 (41) – Ref. – Ref.
C 54.0 (161) 63.3 (19) 0.33 0.68 [0.31–1.48] 0.24 0.62 [0.28–1.38] 54.2 (116) 60.6 (63) 0.28 0.77 [0.48–1.24] 0.47 0.83 [0.51–1.36]
Table 3.  Genotype and allele frequencies of MUC1 rs4072037 in ASSD-ILD+ and IPF patients. ASSD: 
antisynthetase syndrome; CI: confidence interval; ILD: interstitial lung disease; IPF: idiopathic pulmonary 
fibrosis; OR: odds ratio. Statistically significant results are highlighted in bold. *Adjusted for age and sex.
ASSD-ILD+ % (n) IPF% (n) p OR [95% CI] p* OR [95% CI]*
Genotypes
TT 19.5 (29) 32.7 (57) – Ref. – Ref.
TC 53.0 (79) 48.3 (84) 0.03 1.85 [1.07–3.18] 0.05 1.91 [0.99–3.68]
CC 27.5 (41) 19.0 (33) 0.006 2.44 [1.29–4.63] 0.007 2.84 [1.33–6.08]
Alleles
T 46.0 (137) 56.9 (198) – Ref. – Ref.
C 54.0 (161) 43.1 (150) 0.006 1.55 [1.14–2.12] 0.007 1.68 [1.16–2.44]
Figure 1.  Serum KL-6 levels in patients with antisynthetase syndrome (ASSD), healthy controls and patients 
with idiopathic pulmonary fibrosis (IPF). (a) Comparison between ASSD patients and healthy controls. (b) 
Comparison between patients with ILD associated with ASSD (ASSD-ILD+) and IPF patients. P values were 
adjusted for age, sex, and smoking history. Horizontal bars indicate the mean value of each study group.
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fied by sex, being serum KL-6 levels similar between women with ASSD-ILD+ and those with IPF and also 
between men with ASSD-ILD+ and those with IPF (1383.20 ± 993.93 U/mL vs. 1561.14 ± 894.01 U/mL, p = 0.87; 
2232.91 ± 1312.30 U/mL vs. 1707.91 ± 965.94 U/mL, p = 0.12, respectively).
Influence of MUC1 rs4072037 on serum KL‑6 levels. We also assessed the influence of MUC1 
rs4072037 genotypes and alleles on serum levels of KL-6 in ASSD patients, IPF patients and healthy controls 
(Fig.  2). It was interesting to note that, regardless of the study group analyzed, individuals with the MUC1 
rs4072037 CC genotype exhibited the highest serum levels of KL-6, whereas those with TC genotype had inter-
mediate serum KL-6 levels compared to those carrying the reference TT genotype. Consequently, individuals 
with MUC1 rs4072037 C allele had higher serum KL-6 levels than those carrying the reference T allele. Although 
these results were statistically significant in the group of patients with IPF and healthy controls, they did not 
reach statistical significance in ASSD patients (Fig.  2). This was also the case when we specifically analyzed 
ASSD-ILD+ patients.
Discussion
The study of biomarkers associated with the susceptibility and severity to develop ASSD constitutes a field of 
growing interest. In this regard, mucin-1/KL-6 has been proposed as a serum biomarker useful to detect the 
presence of ILD, to evaluate disease activity and to predict clinical outcomes in various types of ILDs, such as 
IPF and CTD-ILD, including PM and  DM5,7,13,16,17. However, after conducting a literature review, only a recent 
study aimed to assess serum KL-6 levels in a small cohort of Chinese ASSD  patients38. Of note, Takei et al. sug-
gested that changes in KL-6 levels could be a predictive factor for the recurrence of  ASSD39. In addition, there 
is no information on the role of the MUC1 rs4072037 polymorphism in ASSD patients. Accordingly, in this 
study we aimed to determine, for the first time, the potential implication of mucin 1 /KL-6, at the genetic and 
serological level, as a biomarker of ASSD susceptibility as well as for the differential diagnosis between ASSD-
ILD+ and IPF patients.
In this study, we disclosed that the MUC1 rs4072037 C allele was associated with a higher risk of developing 
ASSD compared to healthy controls. In addition, our results showed no association of MUC1 rs4072037 with 
the presence/absence of ILD and anti Jo-1 antibody status, suggesting that its influence is unrelated to the most 
common clinical features of the disease. Furthermore, we found a significant increase in serum levels of KL-6 in 
patients with ASSD related to controls. In accordance with our results, it is well known that serum KL-6 levels 
are normal in healthy individuals and elevated in other  CTDs7,9,25,27,28.
Figure 2.  Serum KL-6 levels in patients with antisynthetase syndrome (ASSD), patients with idiopathic 
pulmonary fibrosis (IPF) and healthy controls, according to their genotype and allele for MUC1 rs4072037. Bars 
indicate the mean value.
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Our study also revealed that MUC1 rs4072037 C allele has a different distribution between ASSD-ILD+ and 
IPF patients while serum KL-6 levels were similar between both groups, regardless of the sex of the patients. 
These results may appear to be controversial at first glance. However, it is plausible to think that the different 
genetic distribution of rs4072037 found between ASSD-ILD+ and IPF patients is not reflected in their serum 
KL-6 levels due to molecular regulations that may occur at the epigenome, transcriptome or post-transcriptional 
level. In this regard, it should also be noted that, in keeping with our results regarding KL-6 levels, there was no 
significant difference in serum KL-6 levels between 43 ASSD-ILD patients and 34 IPF patients from  China38. In 
addition, Ishii et al. reported that KL-6 serum levels cannot be used to distinguish patients with IPF from those 
with non-specific interstitial  pneumonia40. Taking all this into account, although the measurement of KL-6 allows 
us to differentiate a healthy subject from an ILD patient, our results indicate that it would not be useful for the 
discrimination between ASDD-ILD + and IPF patients. On the contrary, our genetic results support the use of 
MUC1 rs4072037 genotyping as a diagnostic tool to identify patients with ILD who do not meet criteria for IPF 
and that, in case of having the MUC1 rs4072037 C allele, can have a greater risk of presenting ASSD. In this 
sense, this genetic biomarker may help clinicians to generate a higher level of suspicion towards the diagnosis 
of ASSD, irrespective of their serum levels of KL-6.
In line with the above, we previously reported that a polymorphism in MUC5B gene, that codifies for another 
relevant lung mucin, showed genetic differences between ASSD-ILD+ and  IPF31. Taken together, these findings 
suggest that mucin genetic polymorphisms may influence the phenotype expression of diseases associated with 
ILD. This is crucial given the diverse prognosis and therapeutic options of each disease. Given that the frequency 
of ASSD patients seen in ILD units is  high41, these genetic biomarkers can constitute an affordable and easy-to-
perform complementary tool to contribute to the early recognition and management of this entity.
Finally, in our study we found an association between MUC1 rs4072037 C allele and higher serum KL-6 
levels. This finding was in line with previous reports that included healthy controls and patients with diverse 
lung  diseases9,14,18.
In conclusion, our results suggest that the presence of the MUC1 rs4072037 C allele increases the risk of ASSD. 
It could be used as a genetic biomarker for the differential diagnosis between patients with ASSD-ILD+ and IPF. 
In addition, KL-6 can be a good marker of ILD regardless of the underlying condition.
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